Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer, Journal of Medical Genetics, vol.53, issue.7, pp.465-71, 2016. ,
Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth? Breast, vol.22, pp.1026-1059, 2013. ,
An overview of triple-negative breast cancer, Arch Gynecol Obstet, vol.293, issue.2, pp.247-69, 2016. ,
Triple-negative breast cancer, N Engl J Med, vol.363, issue.20, pp.1938-1986, 2010. ,
Fertility after breast cancer treatment, Eur J Obstet Gynecol Reprod Biol, vol.173, pp.13-21, 2014. ,
Breast cancer and fertility: an update, Curr Opin Support Palliat Care, vol.9, issue.3, pp.285-93, 2015. ,
An overview of pregnancy and fertility issues in breast cancer patients, Ann Med, vol.47, issue.8, pp.673-681, 2015. ,
Genetics of breast cancer: a topic in evolution, Ann Oncol, vol.26, issue.7, pp.1291-1300, 2015. ,
Evaluation of treatment outcomes of triple-negative breast cancer, J Cancer Res Ther, vol.12, issue.1, pp.150-154, 2016. ,
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients, Breast Cancer Res Treat, vol.115, pp.359-63, 2009. ,
Efficacy of neoadjuvant cisplatin in triplenegative breast cancer, J Clin Oncol, vol.28, pp.1145-53, 2010. ,
Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas, Clin Cancer Res, vol.12, pp.1533-1542, 2006. ,
Breast cancer subtypes and the risk of local and regional relapse, J Clin Oncol, vol.28, pp.1684-91, 2010. ,
breast cancer subtypes, and survival in the Carolina breast cancer study, JAMA, vol.295, pp.2492-2502, 2006. ,
Triple-negative breast cancer: clinical features and patterns of recurrence, Clin Cancer Res, vol.13, pp.4429-4434, 2007. ,
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer, Breast Cancer Res Treat, vol.132, pp.793-805, 2012. ,
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes, Clin Cancer Res, vol.13, pp.2329-2334, 2007. ,
Breast cancer molecular subtypes respond differently to preoperative chemotherapy, Clin Cancer Res, vol.11, pp.5678-5685, 2005. ,
Survival outcomes for patients with metastatic triplenegative breast cancer: implications for clinical practice and trial design Clin Breast Cancer, vol.9, pp.29-33, 2009. ,
Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation Cancer, vol.115, pp.946-951, 2009. ,
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer, J Clin Oncol, vol.26, issue.8, pp.1275-81, 2008. ,
DOI : 10.1200/jco.2007.14.4147
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy, J Clin Oncol, vol.28, pp.375-379, 2010. ,
DOI : 10.1200/jco.2008.20.7019
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis, J Natl Cancer Inst, vol.97, issue.3, pp.188-94, 2005. ,
Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up, Ann Oncol, vol.10, issue.1, pp.47-52, 1999. ,
DOI : 10.1023/a:1008337009350
URL : https://academic.oup.com/annonc/article-pdf/10/1/47/19477127/10-1-47.pdf
Neoadjuvant chemotherapy in operable breast cancer, Eur J Cancer, vol.27, issue.12, pp.1668-71, 1991. ,
DOI : 10.1016/0277-5379(91)90442-g
Effect of preoperative chemotherapy on localregional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18, J Clin Oncol, vol.15, issue.7, pp.2483-93, 1997. ,
Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18, J Natl Cancer Inst Monogr, issue.30, pp.96-102, 2001. ,
DOI : 10.1093/oxfordjournals.jncimonographs.a003469
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27, J Clin Oncol, vol.26, issue.5, pp.778-85, 2008. ,
DOI : 10.1200/jco.2007.15.0235
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902, J Clin Oncol, vol.19, issue.22, pp.4224-4261, 2001. ,
Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer, J Clin Oncol, vol.27, issue.15, pp.2474-81, 2009. ,
Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study, J Natl Cancer Inst, vol.100, issue.8, pp.552-62, 2008. ,
Capecitabine in addition to anthracycline-and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study, J Clin Oncol, vol.28, issue.12, pp.2015-2038, 2010. ,
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neoadjuvant chemotherapy trials, Breast Cancer Res Treat, vol.125, issue.1, pp.145-56, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00589967
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomized controlled superiority trial with a parallel HER-2 negative cohort, Lancet, vol.375, issue.9712, pp.377-84, 2010. ,
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial, Ann Oncol, vol.22, issue.2, pp.301-307, 2011. ,
Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study ,
DOI : 10.1158/0008-5472.sabcs10-s3-2
A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate, Cancer Treat Rep, vol.63, pp.1727-1760, 1979. ,
NSABP Protocol B-27. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel, Oncology (Huntingt), issue.6, pp.37-40, 1997. ,
Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies, Semin Oncol, vol.25, issue.2, pp.31-36, 1998. ,
Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer, J Clin Oncol, vol.13, pp.547-52, 1995. ,
A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer, Ann Oncol, vol.9, pp.1179-84, 1998. ,
Preoperative chemotherapy for women with operable breast cancer, Cochrane Database Syst Rev, vol.2, p.5002, 2007. ,
Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer, J Clin Oncol, vol.27, pp.2938-2983, 2009. ,
on behalf of the EORTC 10994/BIG 1-00 Study Investigators. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial, Lancet Oncol, vol.12, pp.527-566, 2011. ,
Neoadjuvant treatment with trastuzumab in HER2positive breast cancer: results from the GeparQuattro study, J Clin Oncol, vol.28, pp.2024-2055, 2010. ,
and the Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensifi ed chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast canceroutcome on prognosis, Ann Oncol, vol.22, pp.1999-2006, 2011. ,
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups, J Clin Oncol, vol.29, pp.3351-57, 2011. ,
Pathological assessment of response to induction chemotherapy in breast cancer, Cancer Res, vol.46, pp.2578-81, 1986. ,